<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary hypertension in adults with congenital heart disease: Disease-specific management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary hypertension in adults with congenital heart disease: Disease-specific management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary hypertension in adults with congenital heart disease: Disease-specific management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Frantz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H102241079"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Approximately 3 to 10 percent of patients with congenital heart disease (CHD) develop pulmonary hypertension (termed pulmonary hypertension-congenital heart disease [PH-CHD]) [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Epidemiology'</a>.)</p><p>Disease-specific management, shunt closure, and transplantation for adults with PH-CHD are discussed here. The clinical manifestations, diagnosis, general management, and prognosis of PH-CHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis"</a>.)</p><p class="headingAnchor" id="H1745063242"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension (PH)</strong> – PH is defined as a mean pulmonary artery pressure (PAP) &gt;20 mmHg at rest [<a href="#rid3">3</a>]. This threshold for diagnosis is lower than the previously used threshold of ≥25 mmHg [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension-congenital heart disease (PH-CHD)</strong> – Patients with PH-CHD have a variety of types of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). In patients with PH-CHD, PH is commonly but not always caused by CHD. The most common type of PH-CHD is congenital shunt-related pulmonary arterial hypertension (PAH). (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Classification'</a> and  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary arterial hypertension (PAH)</strong> – PAH is a type of PH diagnosed by demonstration of a mean PAP ≥20 mmHg and a pulmonary vascular resistance (PVR) ≥2 Wood units (WU), along with exclusion of other types of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). This definition of &gt;2 WU was revised from &gt;3 WU in the 2022 European Society of Cardiology/European Respiratory Society guidelines to reflect data regarding the prognostic significance of PVR &gt;2 WU [<a href="#rid5">5</a>]. However, for treatment purposes, PVR &gt;3 WU is utilized since data regarding utility of treatment for PVR 2 to 3 WU are not available. Severe PAH is identified by a PVR ≥5 WU [<a href="#rid6">6</a>]. PAH associated with CHD (PAH-CHD) is one of many types of PAH. Eisenmenger syndrome is the most severe form of congenital shunt-related PAH. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 1: Pulmonary arterial hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eisenmenger syndrome</strong> – This disorder is the most severe form of congenital shunt-related PAH and is characterized by the triad of large intra- or extracardiac defect with an initial systemic-to-pulmonary shunt (ventricular, atrial, or great artery  (<a class="graphic graphic_table graphicRef55944" href="/z/d/graphic/55944.html" rel="external">table 2</a>)), PAH with shunt reversal (right-to-left) or bidirectional shunting, and resulting hypoxemia with cyanosis  (<a class="graphic graphic_figure graphicRef52487 graphicRef70502" href="/z/d/graphic/52487.html" rel="external">figure 1A-B</a>) [<a href="#rid7">7,8</a>]. The pulmonary arterial disease in Eisenmenger syndrome is caused by increased pulmonary blood flow and/or elevated PAP.</p><p></p><p class="headingAnchor" id="H3718446173"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Disease-specific therapy includes primary therapy directed at the underlying cause of PH and therapy directed at the pathophysiologic process (eg, pulmonary arterial hypertension [PAH]). Disease-specific therapy differs among the various causes and groups of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>) and is administered along with general management of PH-CHD, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 1</strong> – Most patients with PH-CHD have group 1 PH (PAH). For patients with group 1 PH, there is generally no effective therapy for the underlying cause of PAH, and PAH-specific therapy is directed at PAH itself. (See <a class="local">'PAH-specific therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 2</strong> – For patients with group 2 PH (PH due to left heart disease), the mainstay of treatment is optimized management of the underlying left heart disease (eg, heart failure, mitral valve disease, or aortic valve disease). (See  <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 3</strong> – For patients with group 3 PH (PH due to lung disease and/or hypoxia), management includes treatment of the underlying condition (ie, cause of hypoxemia) and correction of hypoxemia with supplemental oxygen. Patients with PH related to interstitial lung disease or combined pulmonary fibrosis and emphysema may benefit from therapy with inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 4</strong> – For patients with group 4 PH (chronic thromboembolic PH), therapy includes surgical thromboendarterectomy or, for inoperable chronic thromboembolic PH, PAH-specific therapy or pulmonary balloon angioplasty. (See  <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy"</a> and  <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 5</strong> – Patients with group 5 PH have a variety of disorders with unclear or multifactorial mechanisms for PH. Treatment is available for some of the causes of group 5 PH, such as sarcoidosis, vasculitis, and PH associated with myeloproliferative disorders. (See  <a class="medical medical_review" href="/z/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">"Treatment of pulmonary sarcoidosis: Initial approach"</a> and  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="headingAnchor" id="H2939703428"><span class="h1">PAH-SPECIFIC THERAPY</span><span class="headingEndMark"> — </span>Pulmonary arterial hypertension (PAH)-specific therapy is widely accepted for use in selected patients with group 1 PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>), but consensus on a therapeutic approach to PAH-specific therapy for PH-CHD with group 1 PH (PAH-CHD) is lacking. There is limited evidence on the use of PAH-specific therapy in patients with PAH-CHD and tremendous variability in the anatomy and hemodynamics among patients with PAH-CHD. Thus, considerable expertise is required to achieve optimal results when using PAH-specific therapy to treat PAH-CHD.</p><p>The medical treatment strategy for patients with PAH-CHD is mainly based on expert opinion rather than clinical trials [<a href="#rid9">9</a>]. Most pivotal trials of PAH medications in this population have included a small number of patients with fully repaired simple congenital defects, but have excluded patients with residual defects. Case series and the experience of expert centers have provided some support for the use of PAH therapies in PAH-CHD with residual defects.</p><p class="headingAnchor" id="H1658642954"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Hemodynamic cardiac catheterization is required before deciding on PAH-targeted therapy for patients with PH-CHD, as noninvasive evaluation of PH has not been standardized for patients with CHD. (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Confirmation of diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 1</strong> – PAH-specific therapy is suggested in selected patients with group 1 PH (ie, PAH-CHD)  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">Management of PH in patients with Fontan circulation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">"Management of complications in patients with Fontan circulation", section on 'Pulmonary vasodilator therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group 2</strong> – By contrast, PAH-specific therapy is <strong>not</strong> routinely used to treat patients with group 2 PH (PH due to left heart disease) given risk of harm and lack of convincing evidence of benefit. (See  <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Targeted therapy for pulmonary hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Groups 3, 4, or 5</strong> – For patients with groups 3, 4, or 5 PH, PAH-specific therapy is used only after carefully weighing the potential risks and benefits on a case-by-case basis. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p>The following concepts are useful in selecting candidates for PAH-specific therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid with elevated left heart filling pressures</strong> – If left heart filling pressures are elevated, PAH-targeted therapy is generally contraindicated due to risk of aggravating pulmonary vascular congestion and hypoxemia. Thus, as noted above, PAH-specific therapy is generally avoided in patients with group 2 PH. (See  <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Targeted therapy for pulmonary hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications with normal left heart filling pressures</strong> – In the presence of normal left heart filling pressures and elevated pulmonary vascular resistance (PVR), PAH-targeted therapy may be helpful in the following settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Right heart failure </strong>– If elevated PVR appears to be contributing to right heart dysfunction either at rest or during activity, PH-targeted therapy may be helpful in alleviating dyspnea and right heart failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Right-to-left shunt</strong> – In patients with elevated PVR and right-to-left shunt either at rest or during exercise, PH-targeted therapy may lessen the degree of shunt and improve hypoxemia and symptoms.</p><p></p><p class="headingAnchor" id="H2712146724"><span class="h2">Agent selection</span></p><p class="headingAnchor" id="H1415506458"><span class="h3">General approach</span><span class="headingEndMark"> — </span>The approach to PAH-specific therapy for patients with PAH-CHD is generally similar to that for group 1 PAH. Sequential combination therapy is used in patients with PAH-CHD not meeting treatment goals [<a href="#rid5">5</a>].</p><p>Decisions regarding PAH-specific therapy are based upon a comprehensive assessment of risk (low, intermediate, or high) based on multiple clinical features, including World Health Organization (WHO) functional class  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef115237" href="/z/d/graphic/115237.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Baseline risk assessment'</a>.)</p><p>For patients with PAH-CHD with shunts, avoidance of central lines is of particular concern given the risks of paradoxical emboli and infectious complications. Accordingly, when parenteral therapy is indicated, subcutaneous <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> may be used to avoid use of an indwelling line.</p><p class="headingAnchor" id="H3351206354"><span class="h3">Calcium channel blocker not used</span><span class="headingEndMark"> — </span>A key difference between the management of PAH-CHD and that of idiopathic PAH is that calcium channel blockers are <strong>not</strong> used to treat PAH-CHD, and routine acute vasodilator testing is <strong>not</strong> used to guide use of calcium channel blocker therapy in patients with PAH-CHD [<a href="#rid5">5</a>]. An exception is that patients with PAH with small or closed congenital shunts may be candidates for acute vasodilator testing as a guide to calcium channel blocker therapy, as they may respond similarly to patients with idiopathic PAH [<a href="#rid10">10</a>].</p><p>As discussed below, acute vasodilator testing may be performed to guide decisions on whether to close shunt lesions in patients with PAH-CHD. (See <a class="local">'Shunt closure'</a> below.)</p><p class="headingAnchor" id="H4019869665"><span class="h2">Effects in patients with PAH-CHD</span><span class="headingEndMark"> — </span>Limited data are available on the efficacy of PAH-specific therapy for patients with PAH-CHD or Eisenmenger syndrome, and an impact on prognosis has not been established.</p><p>An effect of PH-specific therapy on survival has not been established. A single-center retrospective analysis with propensity score matching of 229 patients with Eisenmenger syndrome found a significant association between pulmonary vasodilator therapy (<a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, or <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>) and improved survival [<a href="#rid11">11</a>]. However, the presence of bias due to confounding variables cannot be excluded even with propensity score matching. A multicenter retrospective study including 1098 patients with Eisenmenger syndrome found that although PAH-specific therapy was a predictor of improved survival in a univariate Cox regression analysis, it did not remain a predictor of survival in a multivariate model [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1755395756"><span class="h3">Endothelin receptor antagonist</span><span class="headingEndMark"> — </span>Endothelin-1-triggered smooth muscle constriction results in diffuse vasoconstriction in the pulmonary arterial bed in patients with PAH, including those who have PAH on the basis of PH-CHD and Eisenmenger syndrome. Thus, the use of PAH-specific therapy to promote pulmonary vasodilation in this clinical setting is conceptually appealing. Among the endothelin receptor antagonists, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, a dual endothelin receptor antagonist, is approved in Eisenmenger patients who are functional class III or IV. Other endothelin receptor antagonists (eg, <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>) show favorable hemodynamic effects in patients with PH-CHD.</p><p>The clinical efficacy of endothelin receptor antagonist therapy for patients with Eisenmenger syndrome is uncertain, given conflicting results of two randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>The MAESTRO trial evaluated endothelin receptor antagonist therapy in 226 patients with Eisenmenger syndrome with WHO functional class II to IV. Patients were randomly assigned to <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a> 10 mg once daily or placebo for 16 weeks [<a href="#rid13">13</a>]. Patients were aged ≥12 years old and had simple or complex congenital cardiac defects; patients with Down syndrome or background PAH therapy were eligible. The mean change in six-minute walk distance (6MWD) was not significantly improved in the macitentan group (18.3 versus 19.7 m in the placebo group). There was an unexpectedly large improvement in 6MWD in the placebo group. N-terminal pro-B-type natriuretic peptide levels were significantly decreased with macitentan versus placebo (ratio of geometric means 0.80; 95% CI 0.68-0.94); PVR also decreased. A hemoglobin decrease from baseline of ≥2 g/dL occurred in 36 percent of patients treated with macitentan versus 8.9 percent of patients receiving placebo. The results of the MAESTRO trial differ from those of the smaller <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">Bosentan</a> Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) comparing bosentan and placebo [<a href="#rid14">14</a>]. Of note, the MAESTRO trial included a more heterogeneous study population than the BREATHE-5 trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Support for <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> therapy in selected patients with Eisenmenger syndrome comes from the BREATHE-5 trial, in which 54 treatment-naïve patients with WHO functional class III Eisenmenger syndrome with simple cardiac defects and without Down syndrome were randomly assigned to oral bosentan or placebo [<a href="#rid14">14</a>]. The 6MWD significantly improved (mean 53 m), PVR fell significantly by 472 dyn-s/cm<sup>5</sup>, and mean pulmonary artery pressure (PAP) fell by 5.5 mmHg with oral bosentan compared with placebo.</p><p></p><p class="headingAnchor" id="H4199321912"><span class="h3">PDE-5 inhibitor</span><span class="headingEndMark"> — </span>Phosphodiesterase-5 (PDE-5) inhibitors (<a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>) show favorable functional and hemodynamic results in patients with PH-CHD, but limited studies are available [<a href="#rid15">15</a>]. A trial randomly assigned 28 patients with Eisenmenger syndrome in WHO functional class II or III to tadalafil or placebo for six weeks followed by a two-week washout period and crossover to the other drug [<a href="#rid16">16</a>]. There was a significant improvement in 6MWD (mean difference 35.4 m) and WHO functional class (mean 1.96 versus 2.12) with tadalafil compared with placebo. Tadalafil significantly decreased PVR with no significant change in systemic vascular resistance.</p><p>A single-center retrospective study of 121 patients with Eisenmenger syndrome found that <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> therapy was significantly associated with survival on multivariate analysis [<a href="#rid17">17</a>]. However, bias caused by residual confounding could not be excluded.</p><p class="headingAnchor" id="H3022885341"><span class="h3">Combination endothelin receptor antagonist plus PDE-5 inhibitor</span><span class="headingEndMark"> — </span>The efficacy of adding a PDE-5 inhibitor to an endothelin receptor antagonist is uncertain, as limited studies are available on combination therapy [<a href="#rid18">18,19</a>]. In a study of 21 patients with Eisenmenger syndrome, all patients were treated with <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> for nine months [<a href="#rid19">19</a>]. Patients were randomly assigned to receive <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> or placebo for three months, and a crossover was performed for the last three months. An improvement in 6MWD and reduction in PVR were observed with bosentan therapy, although there was no control group for this part of the study. The addition of sildenafil to bosentan did not significantly improve the 6MWD (21 versus 8 m with placebo) but significantly improved systemic oxygen saturation at rest (+2.9 versus -1.8 percent with placebo). The evidence for the combination of PDE-5 inhibitor and endothelin receptor antagonist in other forms of PAH is very strong, which may provide some additional rationale for this approach in PH-CHD. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Combination oral therapy'</a>.)</p><p class="headingAnchor" id="H2729554589"><span class="h3">Prostacyclin pathway agonists</span><span class="headingEndMark"> — </span>Small observational studies suggested improvement compared with baseline assessment in patients with Eisenmenger syndrome on exercise tolerance and PAP with long-term use of prostacyclin analogs <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> or <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> [<a href="#rid20">20-23</a>]. Small observational studies also suggested improvement compared with baseline assessment in exercise tolerance with <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> therapy, though PAP was not significantly changed [<a href="#rid21">21,22</a>].</p><p><a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">Selexipag</a> is an oral prostacyclin receptor (also called IP-receptor) agonist. The IP-receptor is one of five types of prostanoid receptors. Selexipag is approved by the US Food and Drug Administration for treatment of group I PAH, including repaired PH-CHD [<a href="#rid24">24</a>]. Its use in other PH-CHD contexts remains to be explored, though it is anticipated that some patients with PH-CHD with residual shunt may benefit, with careful attention to effects on systemic blood pressure and degree of hypoxemia.</p><p class="headingAnchor" id="H3074993475"><span class="h3">Guanylate cyclase stimulator</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">Riociguat</a>, a soluble guanylate cyclase stimulator, showed favorable effects in the subgroup of patients with PAH associated with fully repaired CHD enrolled in the pivotal Pulmonary Arterial hyperTENsion sGC-stimulator Trial (PATENT) study [<a href="#rid25">25</a>]. Although there are no randomized data for riociguat use in patients with PH-CHD, it is anticipated that some such patients may benefit, with careful attention to potential side effects (systemic hypotension and worsening hypoxemia). Riociguat should not be used in combination with a PDE-5 inhibitor due to risk of hypotension or syncope.</p><p class="headingAnchor" id="H631753870"><span class="h1">SHUNT CLOSURE</span><span class="headingEndMark"> — </span>The role of surgery or device closure of the shunt for the patient with PH-CHD depends on the underlying lesion, pathophysiology, and degree of pulmonary vascular disease. Reversible causes of PH should be sought and corrected. Standard recommendations for shunt closure are applied for patients with an atrial septal defect, ventricular septal defect or patent ductus arteriosus, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1417.html" rel="external">"Management of atrial septal defects in adults", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/116253.html" rel="external">"Management and prognosis of congenital ventricular septal defect in adults", section on 'Indications for VSD closure'</a> and  <a class="medical medical_review" href="/z/d/html/5771.html" rel="external">"Management of patent ductus arteriosus (PDA) in term infants, children, and adults", section on 'Indications for closure'</a>.)</p><p class="headingAnchor" id="H134842719"><span class="h2">For large defects</span></p><p class="headingAnchor" id="H868645994"><span class="h3">With left-to-right shunt</span><span class="headingEndMark"> — </span>Indications for shunt closure in patients with or without PH are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1417.html" rel="external">"Management of atrial septal defects in adults", section on 'Indications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116253.html" rel="external">"Management and prognosis of congenital ventricular septal defect in adults", section on 'Indications for VSD closure'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5771.html" rel="external">"Management of patent ductus arteriosus (PDA) in term infants, children, and adults", section on 'Indications for closure'</a>.)</p><p></p><p class="headingAnchor" id="H1170601258"><span class="h3">With right-to left shunt</span><span class="headingEndMark"> — </span>Surgical or percutaneous intervention for shunt closure is contraindicated in patients with Eisenmenger syndrome, as this is not generally beneficial and may be detrimental.</p><p class="headingAnchor" id="H2941700444"><span class="h2">For small defects</span><span class="headingEndMark"> — </span>Patients with elevated pulmonary vascular resistance and a small atrial septal defect or residual/recurrent shunt following closure require specialty care at an experienced center. Closure of the defect is generally discouraged since it acts as a "pop-off" valve for the right heart, allowing right-to-left shunt flow, offloading the right ventricle, and preserving cardiac output at the expense of some cyanosis.</p><p class="headingAnchor" id="H3353360306"><span class="h1">OTHER INTERVENTIONS</span></p><p class="headingAnchor" id="H15968153"><span class="h2">Shunt creation</span><span class="headingEndMark"> — </span>Percutaneous creation of an atrial level shunt (atrial septostomy) is occasionally performed in patients with PH-CHD when a shunt is not present; this strategy is based on data that survival is improved in patients with PH and persistent shunts compared with those without shunting [<a href="#rid26">26</a>].</p><p>This approach is generally reserved for patients with progressive right heart failure despite appropriate PH therapies. A revised technique for safe creation of a reverse Potts shunt (connection between the left pulmonary artery and the descending thoracic aorta to allow offloading of the right ventricle in patients with PAH with suprasystemic pulmonary artery pressures) has been developed [<a href="#rid27">27</a>]. This technique utilizes a radiofrequency wire to create a controlled connection followed by covered stent placement and serial balloon dilation of the stent to create the shunt. This procedure resulted in substantial durable clinical improvement in three patients that were failing maximal medical therapy.</p><p class="headingAnchor" id="H3547850702"><span class="h2">Intervention for obstructive lesions</span><span class="headingEndMark"> — </span>Another potentially reversible cause of PH-CHD is a left heart obstructive lesion (eg, mitral stenosis), which should be treated according to standard recommendations. (See  <a class="medical medical_review" href="/z/d/html/8140.html" rel="external">"Surgical and investigational approaches to management of mitral stenosis"</a>.)</p><p class="headingAnchor" id="H3796617720"><span class="h1">TRANSPLANTATION</span><span class="headingEndMark"> — </span>Heart and lung transplantation or lung transplantation with congenital defect repair or mechanical circulatory support are alternative advanced therapeutic strategies for selected adults with severe PH with CHD and refractory right heart failure despite medical therapy [<a href="#rid28">28</a>]. Patients with CHD who may require lung or heart-lung transplantation should be evaluated and managed in tertiary care centers with medical and surgical personnel with experience and expertise in the management of congenital heart disease and lung or heart-lung transplantation [<a href="#rid29">29</a>].</p><p>Transplantation should be reserved for severely symptomatic patients, since overall survival with medical management is usually quite good even in patients with severe pulmonary arterial disease [<a href="#rid30">30</a>]. For example, in one report of 37 patients with Eisenmenger syndrome and severe pulmonary arterial hypertension (PAH) managed without transplantation, the one- and three-year survival rates were 97 and 77 percent, respectively [<a href="#rid31">31</a>]. Selection of candidates for lung transplantation and heart-lung transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Lung transplantation'</a> and  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a>.)</p><p>Outcomes are also reasonably good in patients with PAH-CHD who undergo transplantation [<a href="#rid32">32,33</a>]. Short- and long-term survival rates following heart-lung transplantation are similar to the survival noted for other forms of PH. The largest transplantation experience comes from a review of 605 Eisenmenger patients in the United Network for Organ Sharing/International Society for Heart and Lung Transplantation joint thoracic registry [<a href="#rid32">32</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Eisenmenger syndrome was associated with atrial septal defect in 171, ventricular septal defect in 164, multiple congenital anomalies in 68, and patent ductus arteriosus in 32. The most common procedure was heart-lung transplantation (430 patients) compared with 106 bilateral and 69 single lung transplants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient survival was greater with heart-lung transplantation compared with isolated lung transplantation (81 versus 68 percent at 30 days and 70 versus 55 percent at one year). The benefit of heart-lung transplantation was greatest in patients with a ventricular septal defect as the cause of Eisenmenger syndrome, while the outcomes were worst in patients with an atrial septal defect.</p><p></p><p>Longer-term follow-up was provided in a series of 51 patients with Eisenmenger syndrome who underwent heart-lung transplantation [<a href="#rid33">33</a>]. Eight patients (16 percent) died early and the 1-, 5-, and 10-year survival rates were 73, 51, and 28 percent, respectively. These outcomes were the same as those in patients undergoing heart-lung transplantation for other indications.</p><p>The choice of transplant procedure is based upon numerous factors. Cardiac repair with bilateral lung transplantation generally has a more manageable postoperative course and greater functional reserve than single lung transplantation. On the other hand, isolated lung transplantation enables greater use of the limited supply of donor organs, generally requires shorter time on cardiopulmonary bypass, and may allow late reversal of arteriopathy in the remaining native lung. For patients with unsuccessfully repaired or uncorrectable lesions, and/or severely depressed left ventricular function, heart-lung transplantation is the preferred procedure. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/3525.html" rel="external">"Heart-lung transplantation in adults"</a>.)</p><p class="headingAnchor" id="H520354496"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a>.)</p><p class="headingAnchor" id="H4165257118"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of disease-specific therapy</strong> – Disease-specific therapy includes primary therapy directed at the underlying cause of pulmonary hypertension (PH) and therapy directed at the pathophysiologic process (eg, pulmonary arterial hypertension [PAH]-specific therapy). Disease-specific therapy differs among the various causes and groups of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>) and is administered along with general management of pulmonary hypertension-congenital heart disease (PH-CHD). (See <a class="local">'Overview'</a> above and  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection for PAH-specific therapy</strong> – Hemodynamic cardiac catheterization is required to identify patients with PH-CHD who are candidates for PAH-specific therapy as noninvasive evaluation of PH has not been standardized for patients with CHD. (See <a class="local">'Patient selection'</a> above and  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Confirmation of diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent selection for PAH-specific therapy</strong> – The approach to PAH-specific therapy for patients with PAH-CHD is generally similar to that for group 1 PAH.</p><p></p><p class="bulletIndent1">A key exception is that calcium channel blocker therapy is usually not used in patients with PAH-CHD. However, patients with PAH with small or closed congenital shunts may be candidates for acute vasodilator testing as a guide to calcium channel blocker therapy, as they may respond similarly to patients with idiopathic PAH.</p><p></p><p class="bulletIndent1">For patients with PAH-CHD with shunts, avoidance of central lines is of particular concern given the risks of paradoxical emboli and infectious complications. Accordingly, when parenteral therapy is indicated, subcutaneous <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> may be used to avoid use of an indwelling line. (See <a class="local">'Agent selection'</a> above and  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Baseline risk assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of intervention</strong> – The role of interventional treatments for the patient with PH-CHD depends on the underlying lesion, pathophysiology, and degree of pulmonary vascular disease. Reversible causes of PH should be evaluated and corrected. A decision of whether or not to close a defect is based upon factors including the direction of flow, pulmonary vascular resistance (PVR), and the type of defect. (See <a class="local">'Shunt closure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation</strong> – Heart and lung transplantation or lung transplantation with repair of congenital defect are treatment options for selected severely symptomatic patients with Eisenmenger syndrome. (See <a class="local">'Transplantation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58:538.</a></li><li><a class="nounderline abstract_t">van Riel AC, Schuuring MJ, van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 2014; 174:299.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42:563.</a></li><li><a class="nounderline abstract_t">Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16:19.</a></li><li><a class="nounderline abstract_t">Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89:34.</a></li><li><a class="nounderline abstract_t">Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53:733.</a></li><li><a class="nounderline abstract_t">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e698.</a></li><li><a class="nounderline abstract_t">Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121:20.</a></li><li><a class="nounderline abstract_t">Kempny A, Hjortshøj CS, Gu H, et al. Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study. Circulation 2017; 135:1432.</a></li><li><a class="nounderline abstract_t">Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation 2019; 139:51.</a></li><li><a class="nounderline abstract_t">Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48.</a></li><li><a class="nounderline abstract_t">Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120:301.</a></li><li><a class="nounderline abstract_t">Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011; 6:424.</a></li><li><a class="nounderline abstract_t">Sun YJ, Yang T, Zeng WJ, et al. Impact of sildenafil on survival of patients with Eisenmenger syndrome. J Clin Pharmacol 2013; 53:611.</a></li><li><a class="nounderline abstract_t">D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012; 155:378.</a></li><li><a class="nounderline abstract_t">Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31:1124.</a></li><li><a class="nounderline abstract_t">Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003; 91:632.</a></li><li><a class="nounderline abstract_t">Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol 2012; 33:744.</a></li><li><a class="nounderline abstract_t">Cha KS, Cho KI, Seo JS, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol 2013; 112:1834.</a></li><li><a class="nounderline abstract_t">Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol 2013; 168:4117.</a></li><li><a class="nounderline abstract_t">Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:2522.</a></li><li><a class="nounderline abstract_t">Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015; 101:1792.</a></li><li><a class="nounderline abstract_t">Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. J Cardiol 2015; 66:304.</a></li><li><a class="nounderline abstract_t">Anderson JH, Cabalka AK, Frantz RP, et al. Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension. Circ Cardiovasc Interv 2022; 15:e011315.</a></li><li><a class="nounderline abstract_t">Adriaenssens T, Delcroix M, Van Deyk K, Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J 2006; 27:1472.</a></li><li><a class="nounderline abstract_t">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.</a></li><li><a class="nounderline abstract_t">Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223.</a></li><li><a class="nounderline abstract_t">Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.</a></li><li><a class="nounderline abstract_t">Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21:731.</a></li><li><a class="nounderline abstract_t">Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001; 72:1887.</a></li></ol></div><div id="topicVersionRevision">Topic 139770 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794056" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355641" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Definitions and diagnosis of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860028" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2020 ESC Guidelines for the management of adult congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654195" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The remarkable right ventricle of patients with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779519" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19245962" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026774" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979875" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586694" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of Macitentan in Patients With Eisenmenger Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801459" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174418" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21914136" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553708" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of sildenafil on survival of patients with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081251" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202971" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615282" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22349672" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890862" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26699168" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Selexipag for the Treatment of Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135803" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Riociguat for pulmonary arterial hypertension associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25769400" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34930014" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707548" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400015" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8820089" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100899" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Heart-lung or lung transplantation for Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11789765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Heart-lung transplantation for Eisenmenger syndrome: early and long-term results.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
